



18 March 2024

dorsaVi adds real-time facial tracking to AI-powered movement platform

Key highlights

- dorsaVi's AI-powered and touchless movement tracking platform, ViMove⁺, is now capable of real-time facial tracking
- The new feature de-identifies individuals during video capture with facial blurring, enhancing dorsaVi's privacy and compliance practices in line with global security standards
- Real-time facial tracking complements dorsaVi's existing FDA approved sensor technologies, which reinforces dorsaVi as a leader in non-intrusive and accurate human movement analytics
- Future developments aligned with AI-powered movement analysis now underway including upper limb and swing-based modules

Melbourne, Australia, 18 March 2024: dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**), developer of FDA approved wearable sensors and leader in human movement analytics, is pleased to announce it has successfully integrated real-time facial tracking into its suite of AI-powered video tracking capabilities available in the ViMove⁺ platform. The advancement builds upon the successful development of lower limb tracking achieved in September 2023¹.

To maintain dorsaVi's status as a global leader in the field of human movement analysis, the Company has been developing non-intrusive, AI-powered, high-precision movement tracking capabilities within its ViMove⁺ platform leveraging video capture.

The ViMove⁺ platform directly complements dorsaVi's core sensor technology currently used by leading groups including Medtronic² and QBE Insurance Group³. Without requiring physical sensors, ViMove⁺ video AI offers several advantages including the ability to capture and analyse more natural movements as well as improving scalability, margins and delivery costs for the Company.

Real-time facial tracking was an essential feature for de-identifying individuals during video capture through facial blurring. This key product upgrade now allows dorsaVi to provide industry-leading contactless movement analysis, while also complying with stringent ISO27001 and privacy requirements, crucial technical hurdles required before working with enterprise-scale clients.

As part of the Company's AI-focused product development plan, a beta version of the video capture module is being evaluated by 15 US customers before a commercial release occurring in Q4 FY24. The Company is also set to launch an upper limb module in Q1 FY25 and is in the advanced stages of developing a swing-based module, designed to analyse complex movements in sports including golf, tennis and baseball.

¹ See ASX release 6 July 2023

² See ASX release 24 October 2022

³ See ASX release 24 June 2022

Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, said:

"This significant achievement showcases our dedicated in-house AI capabilities. By delivering touchless video solutions that complement our FDA cleared sensors, we reassert our position as the leading provider of human movement tracking globally. Achieving real-time facial tracking allows us to boost our privacy protections which has been crucial in strengthening existing partnerships and establishing new ones. We are excited about the innovative features on the horizon and the prospect of welcoming new clients throughout the year."

The release of this announcement was authorised by the Board of dorsaVi.

– ENDS –

For further information about dorsaVi, please contact:

dorsaVi

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
ar@dorsavi.com

Investors

Jed Pedersen
Vesparum Capital
+61 3 8582 4800
dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com